– ABOUT
CAD FRONTIERS
CAD Frontiers is a transformative initiative addressing coronary artery disease (CAD), the leading cause of premature death globally. With an Australian-led, international team, CAD Frontiers combines multidisciplinary expertise, innovation, strategic leadership, and commercialisation to revolutionise the prevention and treatment of CAD.
The program is advancing the discovery of blood-based biomarkers to detect early, silent CAD using state-of-the-art imaging, multi-omics, and machine learning applied to national datasets including BioHEART and ACDC. These efforts are enabling the development of new diagnostic tools, risk algorithms, and precision medicine approaches.
CAD Frontiers also drives innovation in clinical care pathways, focusing on early detection and effective intervention. By integrating novel endpoints, direct-to-consumer tools, and partnerships with pathology providers, the program accelerates the translation of research into patient care. On the therapeutic front, CAD Frontiers leverages patient-derived models, drug library screening, and tailored preclinical pipelines to discover and test new drugs targeting CAD. Clinical trials are advancing treatments aimed at halting disease progression and preventing heart attacks entirely.
Through cutting-edge science and collaboration, CAD Frontiers is making the next leap in protecting patients at risk of CAD, with the ultimate vision of a world without heart attacks.
BIOPLATORMS PARTNERSHIP
Bioplatforms Australia’s partnership supports access to national state-of-the-art omics facilities, enabling researchers to generate and analyse biological data in pursuit of scientific understanding.